AzTrials
AzTrials

Drug DiscontinuationCLIN-GLP1NCT07387796

Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation

A study testing Discontinuation and Reinitiation of Tirzepatide in people with Drug Discontinuation and Substance Use Disorders, run by The University of Texas at Dallas at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Discontinuation and Reinitiation of Tirzepatide
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited States
Study dates
Oct 2026to Feb 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 18-70 years.
  • Currently on tirzepatide.
  • Currently receiving care from University of Texas- Southwestern (UTSW) Weight Wellness Clinic.
  • Cognitively capable of understanding and signing informed consent.
  • Be proficient in English.

Who cannot join

  • History of major neurological or psychiatric disorders, including substance use disorders that might confound brain imaging results (e.g., stroke, epilepsy, multiple sclerosis, schizophrenia, major depression requiring hospitalization).
  • Diagnosis of Type 2 Diabetes.
  • Current diagnosis of an eating disorder.
  • Use of medications affecting weight other than tirzepatide.
  • Pregnancy or breastfeeding.
  • MR contraindications:
Show all 20Show fewer
  • Heart pacemaker, heart valve replacement, or aortic clips
  • Metal fragments in the eyes, skin, or elsewhere in the body
  • Brain clips or pieces of metal used in aneurysm surgery or intercranial bypass
  • Venous umbrella
  • Pieces of metal in the body resulting from work as a sheet-metal worker or welder
  • Clips placed in an internal organ
  • Prosthetic devices, such as middle ear, eye, joint, or penile implants
  • Joint replacement
  • Hearing aid that cannot be removed
  • Neurostimulator
  • Insulin pump
  • Shunts or stents
  • Metal mesh or coil implants
  • Metal plate, pin, screws, or wires, or any other metal implants

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Samuel H Poelker-Wells, Master of Science contact

972-883-3375

sxp230129@utdallas.edu

Aishwarya Veerkumar, Master of Public Health contact

972-883-3304

Aishwarya.Veerkumar@UTDallas.edu

United States1 site, 1 recruiting
  • Center for BrainHealth

    Dallas, Texas, 75235

    Samuel M Poelker-Wells, Master of Science, 972-883-3375, sxp230129@utdallas.edu

    Aishwarya Veerkumar, Master of Science, Aishwarya.Veerkumar@UTDallas.edu

    Recruiting

Other trials in United States

About this study

Official title: Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) Discontinuation

The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide. Specifically, the study aims to examine how a short pause in tirzepatide affects hunger, mood, sleep, and daily functioning; how stopping and restarting tirzepatide alters brain chemistry and brain responses to food-related images; and how these changes relate to health measures such as quality of life and emotional well-being. There is no comparison group; instead, researchers will assess changes within each participant across three time points: while taking tirzepatide, after stopping it for 3-4 weeks, and after restarting it for 6-8 weeks. Participants will attend three in-person visits lasting approximately 3-4 hours each, during which they will complete interviews, questionnaires, and cognitive tasks; provide a urine sample (pregnancy screening for females); undergo a brain scan using magnetic resonance imaging (MRI) and MR spectroscopy (MRS); and receive a kit to provide a small stool sample. Participants will also complete two brief check-in phone calls between visits and the online BrainHealth Index between sessions, which includes surveys and cognitive tasks. All changes to tirzepatide use will occur under the supervision of a study physician to support participant safety and comfort, and the total study duration is approximately 13 weeks.

Read the detailed description

This study specifically recruits individuals currently being prescribed for tirzepatide. The experimental design will consist of a brief discontinuation of the drug for roughly 3-4 weeks followed by a reinitiation of the medication. Prescription and administration of tirzepatide is done as part of normal patient care and is not a component of the study.

Being tested
Discontinuation and Reinitiation of Tirzepatide
Keywords
Tirzepatide, Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes
Medical subject headings
Substance-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Discontinuation and Reinitiation of TirzepatideOther

    Participants will temporarily pause their tirzepatide medication for 3-4 weeks and then restart it for 6-8 weeks under the supervision of a study physician. The medication change is done only for research purposes to study how stopping and restarting tirzepatide affects brain activity, appetite, mood, and other health measures. During this period, participants will complete MRI scans, behavioral assessments, questionnaires, and provide stool samples across three study visits.

Study groups in NCT07387796
Study groupRoleWhat they receive
Tirzepatide Discontinuation and Re-Initiation ArmExperimentalParticipants in this single-group arm will complete three study visits that occur while they are taking tirzepatide, during a 3-4 week pause from the medication, and after they restart tirzepatide for 6-8 weeks. All medication changes are supervised by a study physician. At each visit, participants will complete interviews, questionnaires, cognitive tasks, magnetic resonance imaging (MRI) brain scans, and provide stool samples. They will also complete two short check-in phone calls and an online BrainHealth Index assessment between visits.
Receives: Other: Discontinuation and Reinitiation of Tirzepatide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From On-Treatment to Discontinuation and Re-Initiation in Food Cue-Evoked BOLD Response in Reward and Salience Brain Regions

    This outcome measures within-participant change in blood-oxygen-level-dependent (BOLD) signal during a food cue reactivity task, assessed using functional magnetic resonance imaging (fMRI).

    BOLD response will be quantified as the mean percent signal change in predefined reward- and salience-related regions of interest (including the ventral striatum and insula) during food image presentation relative to non-food control images. Higher BOLD values indicate greater neural responsivity to food cues.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

Secondary outcomes (26)
  1. Change From Baseline in Resting-State Functional Connectivity Within Salience and Executive Control Networks

    This outcome measures within-participant change in resting-state functional connectivity, assessed using fMRI. Connectivity strength will be calculated using correlation coefficients between predefined brain regions within salience and executive control networks. Higher values indicate stronger functional connectivity.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  2. Change From Baseline in Brain Glutamate Levels

    This outcome measures within-participant change in neurochemical and dopaminergic markers associated with reward processing. Glutamate levels will be measured in the medial prefrontal cortex using magnetic resonance spectroscopy (MRS). Higher values indicate greater metabolite concentration or signal intensity.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  3. Change From Baseline in State Food Craving Severity

    This outcome measure assesses within-participant change in momentary food craving severity. Food cravings will be measured using the Food Cravings Questionnaire-State (FCQ-S), a self-report instrument assessing current craving intensity. Scores range from 15 to 75, with higher scores indicating greater food craving severity.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  4. Change From Baseline in Blood-Brain Permeability Levels

    This outcome measures within-participant change in neurovascular properties of the blood-brain barrier. Blood-brain barrier permeability to water will be measured using phase-contrast arterial spin tagging (WEPCAST). Higher values indicate greater blood-brain barrier permeability.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  5. Change From Baseline in Trait Food Craving Severity.

    This outcome measure assesses within-participant change in habitual food craving frequency and intensity. Trait-level food cravings will be assessed using the Food Cravings Questionnaire-Trait, a self-report questionnaire. Scores range from 21 to 126, with higher scores indicating more frequent and intense food cravings.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  6. Change From Baseline in Addictive-Like Eating Symptoms.

    This outcome measure assesses within-participant change in addictive-like eating behaviors. Addictive-like eating symptoms will be assessed using the Yale Food Addiction Scale 2.0, a self-report measure of addictive-like eating based on diagnostic criteria. Symptom counts range from 0 to 11, with higher scores indicating greater severity of addictive-like eating behavior.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  7. Change From Baseline in Intrusive Food-Related Thoughts.

    This outcome measure assesses within-participant change in the frequency of intrusive food-related thoughts. Intrusive food-related cognitions will be assessed using the Food Noise Questionnaire, a self-report measure consisting of five items assessing persistent and intrusive thoughts about food. Total scores range from 0 to 20, with higher scores indicating greater food noise and more frequent intrusive food-related thoughts.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  8. Change From Baseline in Dietary Pattern Quality.

    This outcome measure assesses within-participant change in dietary behaviors and overall eating patterns. Dietary patterns will be assessed using the Rapid Eating Assessment for Participants - Shortened Version, a self-report questionnaire evaluating habitual dietary behaviors. Total scores range from 13 to 39, with higher scores indicating healthier dietary patterns.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  9. Change From Baseline in Perceived Loss of Control Over Eating.

    This outcome measure assesses within-participant change in perceived loss of control over eating behavior. Perceived loss of control will be assessed using the Loss of Control Over Eating Scale-Short Form, a self-report questionnaire assessing the subjective experience of being unable to control eating. Total scores range from 7 to 35, with higher scores indicating greater perceived loss of control over eating.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  10. Change From Baseline in Psychological Responsiveness to Food Availability.

    This outcome measure assesses within-participant change in psychological responsiveness to the food environment. Responsiveness to food availability will be assessed using the Power of Food Scale, a self-report questionnaire measuring the psychological impact of food availability independent of actual consumption. Scores are calculated as a mean item score ranging from 1 to 5, with higher scores indicating greater psychological impact of food availability.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  11. Change From Baseline in Uncontrolled Eating Behavior.

    This outcome measure assesses within-participant change in uncontrolled eating behavior. Uncontrolled eating will be assessed using the Uncontrolled Eating subscale of the Three-Factor Eating Questionnaire, a self-report measure of tendencies toward loss of control over eating. Subscale scores range from 3 to 36, with higher scores indicating poorer regulation of eating behavior.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  12. Change From Baseline in Mood Disturbance.

    This outcome measure assesses within-participant change in mood disturbance. Mood will be assessed using the Profile of Mood States-Short Form, a validated self-report questionnaire assessing multiple mood domains including tension, depression, anger, vigor, fatigue, and confusion. Mood disturbance will be quantified using the Total Mood Disturbance score, which ranges from -24 to 124, with higher scores indicating greater overall mood disturbance (reflecting higher negative mood and lower vigor).

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  13. Change From Baseline in Perceived Stress.

    This outcome measure assesses within-participant change in perceived psychological stress. Perceived stress will be measured using the Perceived Stress Scale (PSS), a self-report questionnaire assessing the degree to which situations in one's life are appraised as stressful over the past month. Scores range from 0 to 40, with higher scores indicating greater perceived stress.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  14. Change From Baseline in Quality of Life.

    This outcome measure assesses within-participant change in quality of life. Quality of life will be assessed using the World Health Organization Quality of Life-BREF, a 26-item self-report questionnaire assessing perceived quality of life across physical health, psychological health, social relationships, and environmental domains. Total scores range from 26 to 130, with higher scores indicating better overall quality of life.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  15. Change From Baseline in Withdrawal-Related Psychological Symptoms.

    This outcome measure assesses within-participant change in withdrawal-related psychological and behavioral distress during tirzepatide discontinuation. Withdrawal symptoms will be assessed using a Withdrawal Symptom Checklist, a self-report questionnaire assessing appetite and physiological symptoms, eating behavior and perceived control, restrictive dieting and compensatory behaviors, mood and emotional distress, and general physical and functional impairment associated with medication withdrawal. Items are rated on a 5-point scale ranging from 0 (not at all/never) to 4 (very severe/very often) and summed to create a total score. Total scores range from 0 to 128, with higher scores indicating greater withdrawal-related psychological and behavioral distress.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  16. Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire assessing subjective sleep quality over the past month. Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  17. Change From Baseline in Addiction-Related Problem Severity

    This outcome measure assesses within-participant change in addiction-related problem severity across multiple functional domains. Addiction-related severity will be assessed using the Addiction Severity Index, a standardized semi-structured interview administered by trained study personnel. The Addiction Severity Index evaluates seven domains: medical status, employment/support status, alcohol use, drug use, legal status, family/social functioning, and psychological status, based on both past 30-day functioning and lifetime history. Domain-specific composite scores range from 0 to 1, with higher scores indicating greater addiction-related problem severity.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  18. Change From Baseline in Substance Use Frequency and Quantity.

    This outcome measure assesses within-participant change in substance use behavior. Substance use frequency and quantity will be measured using the Timeline Follow-Back (TLFB) method, which captures the number of days and amount of alcohol, nicotine, and cannabis use over the past 30 days. Higher values indicate more frequent or greater substance use.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  19. Change From Baseline in Risky and Impulsive Behavior.

    This outcome measure assesses within-participant change in engagement in risky, impulsive, and self-destructive behaviors. Behaviors will be assessed using the Risky, Impulsive, and Self-Destructive Behavior Questionnaire, a 38-item self-report measure. Frequency responses are binned and summed to create a total score ranging from 0 to 152, with higher scores indicating greater engagement in risky, impulsive, and self-destructive behaviors.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  20. NIH Cognitive Toolbox: Flanker Inhibitory Control and Attention Test

    This outcome measure tests inhibitory control and attentional filtering, relevant to recovery-related changes in top-down regulation. This task takes around 3 minutes. This task contains one practice block, and 1-2 testing blocks. The first testing block contains 25 trails. If the participant passes, then participant will complete a second block as well (25 trials). The scoring will be divided into Accuracy and Reaction Time. Accuracy is scored on a scale of 0 - 5, and if the Accuracy score is greater then or equal to 80%, then the Reaction Time score will be considered. (If less then 80%, then Reaction Time Score will not be used). Reaction Time is scored on a scale of 0 - 5. The Final Score is equal to the Accuracy + Reaction Time. Higher scores indicate greater ability to filter out distracting stimuli and greater ability to focus.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  21. NIH Cognitive Toolbox: Dimensional Change Card Sort Test

    This outcome measure tests mental flexibility, relevant to adaptive reorganization and reduced rigid maladaptive responding. This task takes around 4 minutes. This task contains one practice block and 3 testing blocks. The first two testing blocks contain 5 trials each, and the final block contains 50 trials (10 non-dominant and 40 dominant). If the participant fails to pass the first 2 testing blocks (score of 4/5), the task is over. The scoring will be divided into Accuracy and Reaction Time. Only 40 trials are used to score Accuracy, and is scaled from 0 - 5. If the Accuracy score is greater then or equal to 80%, then the Reaction Time score will be considered. (If less then 80%, then Reaction Time Score will not be used). Reaction Time is scored on a scale of 0 - 5. The Final Score is equal to the Accuracy + Reaction Time. Higher Scores indicate higher cognitive flexibility and attention.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  22. Change from Baseline to Discontinuation in Food-Related Effort-Based Decision-Making

    This outcome measures within-participant changes in willingness to select high-effort/high-reward options in relation to medication status, assessed using computational models. A hierarchical drift diffusion model will estimate parameters reflecting decision dynamics, while a subjective value model will generate participant-level estimates of reward sensitivity, probability sensitivity, and effort cost. Increased effort expenditure after GLP1-RA discontinuation may reflect rebound increases in incentive salience and reward sensitivity.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  23. NIH Cognitive Toolbox: Pattern Comparison Processing Speed Test

    This outcome measure provides a brief index of general cognitive efficiency and helps contextualize executive findings. This task takes around 4 minutes, and includes one continuous testing block. The testing block consists of two visual patterns where the participant had to choose "same" or "not the same". The scores is based off the amount of correct responses in 90 seconds (max is 130), and will be scaled based off participants age. The Mean will be 100, with a standard deviation of 15. Participants with scores greater then 100 will indicate greater cognitive efficiency then of similar age group.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  24. NIH Emotion Toolbox: Negative Effect

    This outcome measure captures emotional distress that may covary with neural markers of recovery, including anger, sadness, and fear. The 7 tasks included in this measure are: Anger, Anger/Hostility, Anger/Physical Aggression, Apathy, Fear/Anxiety, Fear/Somatic Arousal, and Sadness/Depression. Each task takes 2 minutes to complete and contains self reported emotional measures. Participants answer a series of questions, using a scale ranging from 1 ("Never") to 5 ("Always"). Scores are then combined and converted into a "T-score", with a mean of 50 and a standard deviation of 10. Higher T-scores indicate greater emotional distress.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  25. NIH Emotion Toolbox: Perceived Stress

    This outcome measure indexes stress regulation, a clinically meaningful process linked to relapse vulnerability and functional recovery. This task takes 2 minutes and consists of self reported measures. Participants answer a series of questions using a scale ranging from 1 ("Never") to 5 ("Always"). Scores are then combined and converted into a "T-score", with a mean of 50 and a standard deviation of 10. Higher T-scores indicate greater perceived stress and reduced emotional regulation and coping.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

  26. NIH Emotion Toolbox: Meaning and Purpose

    This outcome measure captures positive psychological change and broader recovery-related adaptation. This task takes approximately 2 minutes, and uses a computer-adaptive test (CAT). Participants answer a series of questions using a scale ranging from 1 ("Never") to 5 ("Always"). Scores are then combined and converted into a "T-score", with a mean of 50 and a standard deviation of 10. Higher T-scores indicate greater sense of meaning and purpose, as well as greater feelings of optimism and hopefulness.

    Measured: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2026
  2. Study startOct 2026 (estimated)
  3. Primary completionFeb 2028 (estimated)
  4. Study completionFeb 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07387796
Sponsor's protocol ID
IRB-26-3
Acronym
CLIN-GLP1
Status last verified
Sep 2026
First submitted
8 Jan 2026
Last updated
2 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Lin Z, Jiang D, Liu D, Li Y, Uh J, Hou X, Pillai JJ, Qin Q, Ge Y, Lu H. Noncontrast assessment of blood-brain barrier permeability to water: Shorter acquisition, test-retest reproducibility, and comparison with contrast-based method. Magn Reson Med. 2021 Jul;86(1):143-156. doi: 10.1002/mrm.28687. Epub 2021 Feb 8.

    PubMed 33559214
  • Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004 Mar;13(2):299-310. doi: 10.1023/B:QURE.0000018486.91360.00.

    PubMed 15085902
  • Schulte EM, Gearhardt AN. Development of the Modified Yale Food Addiction Scale Version 2.0. Eur Eat Disord Rev. 2017 Jul;25(4):302-308. doi: 10.1002/erv.2515. Epub 2017 Mar 29.

    PubMed 28370722
  • Racine SE, Horvath SA, Brassard SL, Benning SD. Effort expenditure for rewards task modified for food: A novel behavioral measure of willingness to work for food. Int J Eat Disord. 2018 Dec 31. doi: 10.1002/eat.22999. Online ahead of print.

    PubMed 30597585
  • Lowe MR, Butryn ML, Didie ER, Annunziato RA, Thomas JG, Crerand CE, Ochner CN, Coletta MC, Bellace D, Wallaert M, Halford J. The Power of Food Scale. A new measure of the psychological influence of the food environment. Appetite. 2009 Aug;53(1):114-8. doi: 10.1016/j.appet.2009.05.016. Epub 2009 Jun 12.

    PubMed 19500623
  • Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB.

    PubMed 12900694
  • Karlsson J, Persson LO, Sjostrom L, Sullivan M. Psychometric properties and factor structure of the Three-Factor Eating Questionnaire (TFEQ) in obese men and women. Results from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1715-25. doi: 10.1038/sj.ijo.0801442.

    PubMed 11126230
  • Baker F, Denniston M, Zabora J, Polland A, Dudley WN. A POMS short form for cancer patients: psychometric and structural evaluation. Psychooncology. 2002 Jul-Aug;11(4):273-81. doi: 10.1002/pon.564.

    PubMed 12203741
  • Jurca R, Jackson AS, LaMonte MJ, Morrow JR Jr, Blair SN, Wareham NJ, Haskell WL, van Mechelen W, Church TS, Jakicic JM, Laukkanen R. Assessing cardiorespiratory fitness without performing exercise testing. Am J Prev Med. 2005 Oct;29(3):185-93. doi: 10.1016/j.amepre.2005.06.004.

    PubMed 16168867
  • Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003 Oct 23;1:60. doi: 10.1186/1477-7525-1-60.

    PubMed 14613562
  • Zhang X, Wang H, Kilpatrick LA, Dong TS, Gee GC, Labus JS, Osadchiy V, Beltran-Sanchez H, Wang MC, Vaughan A, Gupta A. Discrimination exposure impacts unhealthy processing of food cues: crosstalk between the brain and gut. Nat Ment Health. 2023 Nov;1(11):841-852. doi: 10.1038/s44220-023-00134-9. Epub 2023 Oct 2.

    PubMed 38094040
  • Vartanian M, Jahanitabesh A, Christensen JF, Staub H, Jensen DEA, Villringer A, Witte AV. Neural responses to visual food cues according to weight and hunger state: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025 Oct;177:106301. doi: 10.1016/j.neubiorev.2025.106301. Epub 2025 Jul 27.

    PubMed 40730315
  • The WHOQOL Group. (1994). The Development of the World Health Organization Quality of Life Assessment Instrument (the WHOQOL). In J. Orley & W. Kuyken (Eds.), Quality of Life Assessment: International Perspectives (pp. 41-57). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-79123-9_4

  • Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71-83. doi: 10.1016/0022-3999(85)90010-8.

    PubMed 3981480
  • Sobell, L. C., & Sobell, M. B. (1992). Timeline Follow-Back. In R. Z. Litten & J. P. Allen (Eds.), Measuring Alcohol Consumption (pp. 41-72). Humana Press. https://doi.org/10.1007/978-1-4612-0357-5_3

Questions about this trial

What is this clinical trial studying?

A study testing Discontinuation and Reinitiation of Tirzepatide in people with Drug Discontinuation and Substance Use Disorders, run by The University of Texas at Dallas at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Samuel H Poelker-Wells, Master of Science (972-883-3375, sxp230129@utdallas.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From On-Treatment to Discontinuation and Re-Initiation in Food Cue-Evoked BOLD Response in Reward and Salience Brain Regions (time frame: Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07387796, which also lists 30 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in